[go: up one dir, main page]

BRPI0720879A2 - microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo. - Google Patents

microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.

Info

Publication number
BRPI0720879A2
BRPI0720879A2 BRPI0720879A BRPI0720879A BRPI0720879A2 BR PI0720879 A2 BRPI0720879 A2 BR PI0720879A2 BR PI0720879 A BRPI0720879 A BR PI0720879A BR PI0720879 A BRPI0720879 A BR PI0720879A BR PI0720879 A2 BRPI0720879 A2 BR PI0720879A2
Authority
BR
Brazil
Prior art keywords
tissue factor
carrier
composition
manufacture
processes
Prior art date
Application number
BRPI0720879A
Other languages
English (en)
Inventor
Pedreño Egea Javier
Ramón Rodríguez Fernámdez-Alba Juan
Caveda Catasús Luis
Original Assignee
Thrombotargets Europe S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombotargets Europe S L filed Critical Thrombotargets Europe S L
Publication of BRPI0720879A2 publication Critical patent/BRPI0720879A2/pt
Publication of BRPI0720879B1 publication Critical patent/BRPI0720879B1/pt
Publication of BRPI0720879B8 publication Critical patent/BRPI0720879B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

microvesícula derivada de fermento carreador de fator de tecido(tf), composição e composição farmacêutica que a compreende e processos para a sua manufatura expõem-se microvesículas derivadas de fermento portadoras de fator de tecido que compreendem uma membrana de fermento e uma proteína de fator de tecido, ou um fragmento da mesma, ou uma proteína de fator de tecido ou um fragmento da mesma fundida a outro peptídeo como uma proteína de fusão tendo atividade prócoagulante. os ditos produtos podem ser usados como agentes pró-coagulantes no tratamento de hemorragias em um paciente.
BRPI0720879A 2006-12-29 2007-12-28 microvesícula derivada de levedura carreadora de fator tissular (tf), composição e composição farmacêutica que a compreende e processos para a sua fabricação BRPI0720879B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06380342A EP1939218A1 (en) 2006-12-29 2006-12-29 Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof
EP06380342.3 2006-12-29
PCT/EP2007/064644 WO2008080989A1 (en) 2006-12-29 2007-12-28 Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0720879A2 true BRPI0720879A2 (pt) 2018-12-26
BRPI0720879B1 BRPI0720879B1 (pt) 2020-11-24
BRPI0720879B8 BRPI0720879B8 (pt) 2021-05-25

Family

ID=38055194

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720879A BRPI0720879B8 (pt) 2006-12-29 2007-12-28 microvesícula derivada de levedura carreadora de fator tissular (tf), composição e composição farmacêutica que a compreende e processos para a sua fabricação

Country Status (13)

Country Link
US (1) US8759294B2 (pt)
EP (2) EP1939218A1 (pt)
JP (1) JP4813603B2 (pt)
CN (1) CN102007144B (pt)
AR (1) AR064720A1 (pt)
AU (1) AU2007341252B2 (pt)
BR (1) BRPI0720879B8 (pt)
CA (1) CA2673996C (pt)
ES (1) ES2394013T3 (pt)
MX (1) MX2009007085A (pt)
PL (1) PL2118134T3 (pt)
RU (1) RU2492184C2 (pt)
WO (1) WO2008080989A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130052647A1 (en) * 2010-02-10 2013-02-28 Marianna Goldrick Methods for fractionating and processing microparticles from biological samples and using them for biomarker discovery
EP2380905A1 (en) * 2010-04-19 2011-10-26 Thrombotargets Europe, S.L. Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof
RU2570636C2 (ru) 2010-07-01 2015-12-10 Аэон Медикс Инк Микровезикулы, происходящие из протопластов клеток, и их применение
JP2012168012A (ja) * 2011-02-14 2012-09-06 Nippon Koden Corp 血管内皮障害を検査するための新規な検査方法および検査用キット
US20150050311A1 (en) * 2012-04-05 2015-02-19 Ludwig-Maximilians-Universitat München Novel method for the preparation of a strain-adapted vaccine
EP2745852A1 (en) * 2012-12-21 2014-06-25 Thrombotargets Europe, S.L. Sealant compositions
EP2759305A1 (en) * 2013-01-24 2014-07-30 Thrombotargets Europe, S.L. Hemostatic compositions
PT3677271T (pt) * 2013-03-13 2023-05-31 Univ Miami Método de isolamento e purificação de microvesículas de sobrenadantes de cultura celular e fluidos biológicos
JP6525971B2 (ja) * 2013-06-11 2019-06-05 タカラ バイオ ユーエスエー， インコーポレイテッド タンパク質富化微細小胞、タンパク質富化微細小胞の作製方法及び使用方法
US11359058B2 (en) 2015-11-18 2022-06-14 Arytha Biosciences, Llc Processes and systems for preparing cellular or viral membranes and nanoparticles
CN106645665B (zh) * 2016-12-27 2019-02-26 北京赛科希德科技股份有限公司 一种凝血酶时间检测试剂
KR102015116B1 (ko) 2018-05-04 2019-10-21 (주)메디톡스 표적 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물로부터 유래한 세포외 소낭 및 그의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994988B1 (en) * 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US7084251B1 (en) * 1987-02-12 2006-08-01 Genentech, Inc. Methods and Deoxyribonucleic acid for the preparation of tissue factor protein
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
AU7129598A (en) * 1997-04-23 1998-11-13 Instrumentation Laboratory S.P.A. Recombinant rabbit tissue factor based prothrombin time reagent
DE19749259A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
JP3859512B2 (ja) * 1999-10-01 2006-12-20 中外製薬株式会社 血液凝固関連疾患の予防及び治療
RU2002111683A (ru) * 1999-10-01 2004-03-10 Тугаи Сейяку Кабусики Кайся (Jp) Профилактика и лечение заболеваний, связанных со свертыванием крови
US6248353B1 (en) * 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
WO2002087594A1 (en) * 2001-04-30 2002-11-07 The Regents Of The University Of California Non-viral vesicle vector for cardiac specific gene delivery
ATE488135T1 (de) * 2001-05-18 2010-12-15 Chugai Pharmaceutical Co Ltd Menschlichen gewebefaktor produzierendes nichtmenschliches knock-in -tier
US20070292490A1 (en) * 2004-06-25 2007-12-20 Valentin Negrouk Production of tissue factor in plants

Also Published As

Publication number Publication date
US20100047335A1 (en) 2010-02-25
ES2394013T3 (es) 2013-01-04
AR064720A1 (es) 2009-04-22
EP2118134A1 (en) 2009-11-18
AU2007341252B2 (en) 2012-05-31
US8759294B2 (en) 2014-06-24
RU2009129143A (ru) 2011-02-10
CN102007144B (zh) 2014-06-04
BRPI0720879B8 (pt) 2021-05-25
EP2118134B1 (en) 2012-08-29
CA2673996A1 (en) 2008-07-10
RU2492184C2 (ru) 2013-09-10
JP4813603B2 (ja) 2011-11-09
EP1939218A1 (en) 2008-07-02
WO2008080989A1 (en) 2008-07-10
AU2007341252A1 (en) 2008-07-10
BRPI0720879B1 (pt) 2020-11-24
PL2118134T3 (pl) 2013-02-28
MX2009007085A (es) 2009-07-09
JP2010514433A (ja) 2010-05-06
CA2673996C (en) 2017-12-12
CN102007144A (zh) 2011-04-06

Similar Documents

Publication Publication Date Title
BRPI0720879A2 (pt) microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
MY154826A (en) Fusion protein capable of binding vegf
BRPI0508670A (pt) proteìnas de buganina modificada, citotoxinas e métodos e usos delas
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
FI4074331T3 (fi) Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
WO2007091250A8 (en) Enzyme replacement therapy for treating lysosomal storage diseases
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
ECSP088463A (es) Antagonistas de activina-actriia y usos para promover el crecimiento óseo
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
DE60135498D1 (de) Produktion von ganzen Antikörpern in prokaryontischen Zellen
DK2231860T3 (da) Polypeptid afledt protein A og i stand til at binde PDGF
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
ES2532985T3 (es) Proteínas quiméricas de toxoide de Shiga
BRPI0710671B8 (pt) uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa
BRPI0620125A8 (pt) método para regulação de redução da função biológica de uma proteína, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma protéina de uma amostra
WO2008093165A3 (en) The use of pgil ohgosaccharyltransferase for o-glycosylating proteins
CL2008003357A1 (es) Procedimiento para obtener una solucion de albumina humana con alta capacidad de union de moleculas que comprende una diafiltracion, estabilizacion con nacl y aminoacidos sin adicion de acidos grasos, pasteurizacion y una segunda diafiltracion.
BR112012006389A2 (pt) agente de depiração peptídica, métodos para produzir um agente de depuração peptídica, e de terapia de pró-droga de enzima direcionada ao anticorpo, e, uso de um peptídeo
BR112013009660A8 (pt) Proteína de fusão com fator de atividade ix, sequência de dna e vetor recombinante
WO2006101387A3 (en) Method for interfering with blood coagulation by modulating cross-beta structures fibril formation
Nicosia et al. Mimicking molecular pathways in the design of smart hydrogels for the design of vascularized engineered tissues
WO2020225799A3 (en) A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2703 DE 25-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.